are glp 1 drugs dangerous Risks of Ozempic, other GLP-1 at center of sweeping lawsuit that kicked off in Philadelphia The promise and peril of

A retrospective cohort study based on administrative claims data of 32,800 exenatide patients who were propensity score matched to patients treated with MET or glyburide found no increased risk for either benign thyroid neoplasms (RR 0.7

Kim H, Baek KH, Lee SY, Ahn SH, Lee SH, Koh JM, et al

OR = 2.40 [1.623.56])with an even greater difference in the proportion using them exclusively for weight loss (2.8% [70.0% of female users] vs

however, this does not account for the reduction in GIPR sensitivity in patients with T2D or the potential differences in GIPR agonism between islet cells and food-intake regulating neurons

doi:10.1038/s41392-024-01931-z Hui H, Farilla L, Merkel P, Perfetti R